Repositioning Candidate Details
| Candidate ID: | R1476 |
| Source ID: | DB13149 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Protein S human |
| Synonyms: | Protein S; Protein S (human); Vitamin K-dependent protein S |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | For use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy . Protein S is administered as part of a cocktail containing several other coagulation factors. |
| DrugBank Pharmacology: | Protein S acts as an anticoagulant serves as a negative feedback mechanism in the coagulation cascade . |
| DrugBank MoA: | Thrombin converts protein C to activated protein C (APC) . Protein S functions as a cofactor for APC and together they proteolytically cleave factor Va and VIIIa . This inhibits the activities of the prothrombinase and tenase complexes respectively and leads to a reduction in thrombin generation. The reduction in thrombin generation suppresses the coagulation cascade preventing additional clotting from occuring. Protein S is suggested to inhibit factors Va and Xa through protein-protein interactions . Protein S is also suggested to inhibit production of factor Xa by the tenase complex by competing for binding to phospholipids via its gamma-carboxyglutamic acid domain. Protein S is thought to exert an anti-inflammatory effect in addition to its anticoagulant properties. The protein S-C4b-binding protein complex is believed to bind to phosphotidylserines on the cell membranes of apoptotic cells and interact with macrophages, signalling them to phagocytose the cell before it can rupture . |
| Targets: | Coagulation factor V antagonist; Coagulation factor X antagonist; Vitamin K-dependent protein C cofactor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|